Full history for every metric is available with a Kvantra account
Zosano Pharma Corporation (ZSAN)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Operating profit | $m | -30 | -57 | |||||
| Net profit | $m | -30 | -29 | -35 | -38 | -33 | -30 | -55 |
| EPS reported | $ | -0.27 | -8.07 | |||||
| Operating cashflow per share | $ | -0.25 | -0.25 | |||||
| Capex per share | $ | 0.05 | 0.05 | |||||
| FCF per share | $ | -0.29 | -0.29 | |||||
| Free cash flow | $m | -33 | -31 | |||||
| Net debt | $m | -2 | -12 | |||||
| Book value equity | $m | 33 | 14 | |||||
| Book value per share | $ | 0.29 | 3.31 | |||||
| Number of shares | m | 112.06 | 4.25 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.60 | 0.17 | |||||
| P/S LTM | x | 67.10 | 3.59 | |||||
| P/FCF LTM | x | -1.60 | -0.08 | |||||
| EV/EBITDA LTM | x | -1.83 | 0.18 | |||||
| EV/Sales LTM | x | 65.10 | -14.30 | |||||
| Earnings Yield LTM | % | -57.17% | -48.19% | |||||
| FCF Yield | % | -62.68% | -1305.5% | |||||
| Quality | ||||||||
| ROE | % | -91.32% | -74.83% | |||||
| ROIC | % | -69.66% | -69.66% | |||||
| Operating margin | % | -3788.0% | -3788.0% | |||||
| Gross margin | % | -1.40% | -1.40% | |||||
| FCF/Sales | % | -4205.5% | -4205.5% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +250.45% | +36.72% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.48 | -5.12 | |||||
| Net Debt/EBITDA | x | 0.06 | 0.06 | |||||
| EBIT/Net interest | x | -157.33 | -157.33 | |||||
| Net debt/market cap | % | -2.97% | -497.74% | |||||
| Net debt/Equity | x | -0.05 | -0.84 | |||||
| Gross debt/equity | x | 0.29 | 0.43 | |||||
Company overview
Zosano Pharma Corporation is a biopharmaceutical enterprise, currently in the clinical development phase, focused on supplying therapeutic agents and other biologically active substances to patients afflicted with migraine using its specialized transdermal microneedle system. Their leading experimental compound, Qtrypta (M207), represents a distinct formulation of zolmitriptan, specifically intended for the swift management of acute migraine episodes. The company commenced operations in 2006 and maintains its principal offices in Fremont, California. Notably, Zosano Pharma Corporation initiated a voluntary Chapter 11 reorganization petition with the U.S. Bankruptcy Court for the District of Delaware on June 1, 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zosano Pharma Corporation (ZSAN)
Zosano Pharma Corporation is a biopharmaceutical enterprise, currently in the clinical development phase, focused on supplying therapeutic agents and other biologically active substances to patients afflicted with migraine using its specialized transdermal microneedle system. Their leading experimental compound, Qtrypta (M207), represents a distinct formulation of zolmitriptan, specifically intended for the swift management of acute migraine episodes. The company commenced operations in 2006 and maintains its principal offices in Fremont, California. Notably, Zosano Pharma Corporation initiated a voluntary Chapter 11 reorganization petition with the U.S. Bankruptcy Court for the District of Delaware on June 1, 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free